Key facts
- This page summarizes Robert Bindert Huizinga's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 May 2021, 17:22.
Robert Bindert Huizinga - 11 May 2021 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)
- Reporting relationship
- Ex Vice President of Research
- Issuer ticker
- AUPH
- Reported as of
- 11 May 2021
- Net transaction value
- +$120,800
- SEC form
- 4
- Accepted by SEC
- 11 May 2021, 17:22:59 UTC
- Next SEC filing
- 08 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Bindert Huizinga
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Bindert Huizinga filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 11 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$120,800.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AUPH
transaction
Common Stock
Options Exercise
- Transaction value
- $120,800
- Shares
- +40,000
- Change %
- +39%
- Price
- $3.02
- Shares after
- 143,592
- Date
- 11 May 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AUPH
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -40,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 11 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $3.02
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
Footnote F2
The shares subject to the options are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. The expiration date was extended as a result of the blackout period.